{
  "url": "https://finance.yahoo.com/news/cynata-therapeutics-asx-cyp-spend-215650280.html?.tsrc=rss&_guc_consent_skip=1756505098",
  "authorsByline": "Simply Wall St",
  "articleId": "472dd5aa17684bf0bcd53abfea81de4e",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-29T21:56:50+00:00",
  "addDate": "2025-08-29T22:06:11.402346+00:00",
  "refreshDate": "2025-08-29T22:06:11.402348+00:00",
  "score": 1.0,
  "title": "Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?",
  "description": "Just because a business does not make any money, does not mean that the stock will go down. For example, although...",
  "content": "Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.\n\nGiven this risk, we thought we'd take a look at whether Cynata Therapeutics (ASX:CYP) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.\n\nThis technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.\n\nWhen Might Cynata Therapeutics Run Out Of Money?\n\nA company's cash runway is calculated by dividing its cash hoard by its cash burn. As at June 2025, Cynata Therapeutics had cash of AU$5.0m and no debt. Looking at the last year, the company burnt through AU$8.8m. So it had a cash runway of approximately 7 months from June 2025. Notably, one analyst forecasts that Cynata Therapeutics will break even (at a free cash flow level) in about 19 months. That means unless the company reduces its cash burn quickly, it may well look to raise more cash. The image below shows how its cash balance has been changing over the last few years.\n\nSee our latest analysis for Cynata Therapeutics\n\nHow Is Cynata Therapeutics' Cash Burn Changing Over Time?\n\nAlthough Cynata Therapeutics reported revenue of AU$2.1m last year, it didn't actually have any revenue from operations. That means we consider it a pre-revenue business, and we will focus our growth analysis on cash burn, for now. As it happens, the company's cash burn reduced by 12% over the last year, which suggests that management may be mindful of the risks of their depleting cash reserves. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.\n\nWhile Cynata Therapeutics is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/8516F834-B011-4BFA-A362-CEB570F394E4?blueprint=4025832&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
    "https://simplywall.st/company/id/8516F834-B011-4BFA-A362-CEB570F394E4/future?blueprint=4025832&utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo",
    "https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global?blueprint=4025832&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=quantum-computing",
    "https://au.finance.yahoo.com/quote/CYP.AX",
    "https://simplywall.st/company/id/8516F834-B011-4BFA-A362-CEB570F394E4/health?blueprint=4025832&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo"
  ],
  "labels": [
    {
      "name": "Non-news"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "cash burn",
      "weight": 0.14927097
    },
    {
      "name": "more cash",
      "weight": 0.13473903
    },
    {
      "name": "cash",
      "weight": 0.13164258
    },
    {
      "name": "Cynata Therapeutics",
      "weight": 0.103210606
    },
    {
      "name": "Cynata Therapeutics Cash Burn",
      "weight": 0.09822783
    },
    {
      "name": "last year",
      "weight": 0.09328271
    },
    {
      "name": "more money",
      "weight": 0.081132814
    },
    {
      "name": "its cash burn",
      "weight": 0.07916288
    },
    {
      "name": "new shares",
      "weight": 0.0790767
    },
    {
      "name": "a free cash flow level",
      "weight": 0.07782855
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.98388671875
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.97998046875
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.97265625
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.80908203125
    }
  ],
  "sentiment": {
    "positive": 0.08400588,
    "negative": 0.60931295,
    "neutral": 0.3066812
  },
  "summary": "Cynata Therapeutics (ASX:CYP) has been identified as a potential concern for its cash burn, defined as its annual (negative) free cash flow. This comes after the company burned through AU$8.8m in the last year. Despite this, the company's cash burn has decreased by 12% over the same period, suggesting it may consider raising more cash to fund faster growth. As at June 2025, Cynata Theraputics had cash of AU$5.0m and no debt. However, one analyst predicts that the company will break even (at a free cash cash flow level) in about 19 months.",
  "shortSummary": "Cynata Therapeutics faces significant cash burn risks and potential debt issues, which may force it to raise additional funds for growth.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "eb4d42b157d54468b0ea886ef080f5ca",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/company/id/8516F834-B011-4BFA-A362-CEB570F394E4/health?blueprint=4025832&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Cynata Therapeutics Balance Sheet Health\nFinancial Health criteria checks 4/6\nCynata Therapeutics has a total shareholder equity of A$6.0M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$7.2M and A$1.2M respectively.\nKey information\n0%\nDebt to equity ratio\nAU$0\nDebt\n| Interest coverage ratio | n/a |\n| Cash | AU$5.05m |\n| Equity | AU$5.98m |\n| Total liabilities | AU$1.22m |\n| Total assets | AU$7.20m |\nRecent financial health updates\nHere's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nSep 21Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?\nMay 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate\nFeb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow\nFeb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth\nSep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nMay 26Recent updates\nHere's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nSep 21Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?\nMay 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate\nFeb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow\nFeb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth\nSep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nMay 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nDec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn\nAug 11Financial Position Analysis\nShort Term Liabilities: CYP's short term assets (A$5.3M) exceed its short term liabilities (A$1.2M).\nLong Term Liabilities: CYP has no long term liabilities.\nDebt to Equity History and Analysis\nDebt Level: CYP is debt free.\nReducing Debt: CYP had no debt 5 years ago.\nBalance Sheet\nCash Runway Analysis\nFor companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.\nStable Cash Runway: CYP has less than a year of cash runway based on its current free cash flow.\nForecast Cash Runway: Insufficient data to determine if CYP has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.\nDiscover healthy companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 21:04 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nCynata Therapeutics Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Dennis Hulme | APP Securities Pty Ltd. |\n| Chris Kallos | MST Financial Services Pty Limited |\n| Raghuram Selvaraju | Rodman & Renshaw, LLC |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global?blueprint=4025832&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=quantum-computing",
      "text": "Results\n23\nExplore top quantum computing companies leading the revolution in next-gen technology, from pioneering hardware manufacturers to innovative software developers. These industry leaders are shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.\n23 companies\nQuantumCTek\nMarket Cap: CN\u00a534.1b\nManufactures and sells quantum information technology enabled information and communication technology security products and services in China.\n688027\nCN\u00a5331.59\n7D\n4.9%\n1Y\n119.6%\nOptowide Technologies\nMarket Cap: CN\u00a59.2b\nEngages in the research, development, production, and sale of precision optics and fiber components in China and internationally.\n688195\nCN\u00a571.25\n7D\n14.6%\n1Y\n226.2%\nIntellect Design Arena\nMarket Cap: \u20b9135.9b\nEngages in the development, marketing, and sale of integrated banking software systems in India and internationally.\nINTELLECT\n\u20b9977.20\n7D\n1.0%\n1Y\n-1.6%\nNagarro\nMarket Cap: \u20ac664.7m\nProvides digital product engineering and technology solutions in Germany, the United States of America, and internationally.\nNA9\n\u20ac52.60\n7D\n-2.6%\n1Y\n-31.7%\nQuanta Computer\nMarket Cap: NT$1.0t\nManufactures, processes, and sells laptop computers and telecommunication products in the United States, Mainland China, the Netherlands, Japan, and internationally.\n2382\nNT$262.50\n7D\n1.5%\n1Y\n-2.1%\nOpen Text\nMarket Cap: US$8.4b\nDesigns, develops, markets, and sells information management software and solutions in North, Central, and South America, Europe, the Middle East, Africa, Australia, Japan, Singapore, India, and China.\nOTEX\nUS$33.07\n7D\n1.3%\n1Y\n3.9%\nWonik IPS\nMarket Cap: \u20a92.0t\nResearches and develops, manufactures, and sells semiconductor, display, and solar cell systems in South Korea.\nA240810\n\u20a940,650.00\n7D\n-0.7%\n1Y\n19.0%\nOxford Instruments\nMarket Cap: UK\u00a31.1b\nOxford Instruments plc provide scientific technology products and services for academic and commercial organizations in the United Kingdom and internationally.\nOXIG\nUK\u00a318.42\n7D\n-1.6%\n1Y\n-19.7%\nFormFactor\nMarket Cap: US$2.3b\nDesigns, manufactures, and sells probe cards, analytical probes, probe stations, thermal systems, cryogenic systems, and related services in the United States and internationally.\nFORM\nUS$29.19\n7D\n0.1%\n1Y\n-40.1%\nNovanta\nMarket Cap: US$4.2b\nProvides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.\nNOVT\nUS$116.41\n7D\n-5.3%\n1Y\n-36.5%\nMicrosoft\nMarket Cap: US$3.8t\nDevelops and supports software, services, devices, and solutions worldwide.\nMSFT\nUS$506.69\n7D\n-0.1%\n1Y\n21.5%\nAlphabet\nMarket Cap: US$2.6t\nOffers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America.\nGOOGL\nUS$212.91\n7D\n3.3%\n1Y\n30.3%\nInternational Business Machines\nMarket Cap: US$228.9b\nProvides integrated solutions and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.\nIBM\nUS$243.49\n7D\n0.6%\n1Y\n20.5%\nTencent Holdings\nMarket Cap: HK$5.4t\nAn investment holding company, provides value-added services, marketing services, fintech, and business services in Mainland China and internationally.\n700\nHK$596.50\n7D\n-0.6%\n1Y\n56.2%\nClearwater Analytics Holdings\nMarket Cap: US$6.2b\nDevelops and provides a Software-as-a-Service (SaaS) solution for automated investment data aggregation, reconciliation, accounting, and reporting services to insurers, investment managers, corporations, institutional investors, and government entities in the United States and internationally.\nCWAN\nUS$20.67\n7D\n-0.9%\n1Y\n-16.6%\nD-Wave Quantum\nMarket Cap: US$5.4b\nDevelops and delivers quantum computing systems, software, and services worldwide.\nQBTS\nUS$15.62\n7D\n0.5%\n1Y\n1,446.5%\nIonQ\nMarket Cap: US$12.9b\nDevelops quantum computers and networks in the United States.\nIONQ\nUS$42.74\n7D\n7.4%\n1Y\n476.0%\nSystena\nMarket Cap: JP\u00a5177.7b\nEngages in the solution and framework design, IT service, business solution, and cloud businesses in Japan.\n2317\nJP\u00a5497.00\n7D\n4.4%\n1Y\n27.4%\nQuantum Computing\nMarket Cap: US$2.6b\nAn integrated photonics company, provides quantum machines to commercial and government markets in the United States.\nQUBT\nUS$15.79\n7D\n-0.3%\n1Y\n2,340.9%\nCheck Point Software Technologies\nMarket Cap: US$20.5b\nDevelops, markets, and supports a range of products and services for IT security worldwide.\nCHKP\nUS$193.14\n7D\n1.4%\n1Y\n0.3%\nRigetti Computing\nMarket Cap: US$5.4b\nThrough its subsidiaries, builds quantum computers and the superconducting quantum processors the United States, the United Kingdom, rest of Europe, Asia, and internationally.\nRGTI\nUS$16.23\n7D\n9.5%\n1Y\n1,671.1%\nHengtong Optic-Electric\nMarket Cap: CN\u00a550.1b\nOperates in the fiber optic communications industry in China, Europe, Latin America, Southeast Asia, the Middle East, and North Africa.\n600487\nCN\u00a520.48\n7D\n9.3%\n1Y\n44.8%\nQuanta Storage\nMarket Cap: NT$34.5b\nResearches, develops, produces, manufactures, and sells data storage and processing equipment, electronic components, optical instruments, and industrial robots in Mainland China, Thailand, the United States, Korea, Netherlands, Japan, and internationally.\n6188\nNT$124.00\n7D\n11.7%\n1Y\n24.6%"
    },
    {
      "url": "https://simplywall.st/company/id/8516F834-B011-4BFA-A362-CEB570F394E4?blueprint=4025832&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
      "text": "Cynata Therapeutics (CYP) Stock Overview\nEngages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 3/6 |\n| Future Growth | 5/6 |\n| Past Performance | 0/6 |\n| Financial Health | 4/6 |\n| Dividends | 0/6 |\nCYP Community Fair Values\nSee what others think this stock is worth. Follow their fair value or set your own to get alerts.\nCynata Therapeutics Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | AU$0.21 |\n| 52 Week High | AU$0.28 |\n| 52 Week Low | AU$0.14 |\n| Beta | 0.78 |\n| 1 Month Change | 23.53% |\n| 3 Month Change | 16.67% |\n| 1 Year Change | 7.69% |\n| 3 Year Change | -38.24% |\n| 5 Year Change | -75.86% |\n| Change since IPO | -95.43% |\nRecent News & Updates\nRecent updates\nHere's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nSep 21Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?\nMay 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate\nFeb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow\nFeb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth\nSep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nMay 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nDec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn\nAug 11Shareholder Returns\n| CYP | AU Biotechs | AU Market | |\n|---|---|---|---|\n| 7D | 10.5% | -6.1% | -0.3% |\n| 1Y | 7.7% | -28.7% | 11.0% |\nReturn vs Industry: CYP exceeded the Australian Biotechs industry which returned -28.7% over the past year.\nReturn vs Market: CYP underperformed the Australian Market which returned 11% over the past year.\nPrice Volatility\n| CYP volatility | |\n|---|---|\n| CYP Average Weekly Movement | 13.9% |\n| Biotechs Industry Average Movement | 11.1% |\n| Market Average Movement | 8.9% |\n| 10% most volatile stocks in AU Market | 19.3% |\n| 10% least volatile stocks in AU Market | 3.5% |\nStable Share Price: CYP's share price has been volatile over the past 3 months compared to the Australian market.\nVolatility Over Time: CYP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 2003 | n/a | Kilian Kelly | www.cynata.com |\nCynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company\u2019s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.\nCynata Therapeutics Limited Fundamentals Summary\n| CYP fundamental statistics | |\n|---|---|\n| Market cap | AU$47.45m |\n| Earnings (TTM) | -AU$9.39m |\n| Revenue (TTM) | AU$2.11m |\nIs CYP overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| CYP income statement (TTM) | |\n|---|---|\n| Revenue | AU$2.11m |\n| Cost of Revenue | AU$0 |\n| Gross Profit | AU$2.11m |\n| Other Expenses | AU$11.50m |\n| Earnings | -AU$9.39m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -0.042 |\n| Gross Margin | 100.00% |\n| Net Profit Margin | -444.45% |\n| Debt/Equity Ratio | 0% |\nHow did CYP perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 21:04 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nCynata Therapeutics Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Dennis Hulme | APP Securities Pty Ltd. |\n| Chris Kallos | MST Financial Services Pty Limited |\n| Raghuram Selvaraju | Rodman & Renshaw, LLC |"
    },
    {
      "url": "https://simplywall.st/company/id/8516F834-B011-4BFA-A362-CEB570F394E4/future?blueprint=4025832&utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo",
      "text": "Cynata Therapeutics Future Growth\nFuture criteria checks 5/6\nCynata Therapeutics is forecast to grow earnings and revenue by 125.7% and 62.2% per annum respectively. EPS is expected to grow by 127.1% per annum. Return on equity is forecast to be 16.9% in 3 years.\nKey information\n125.7%\nEarnings growth rate\n127.13%\nEPS growth rate\n| Biotechs earnings growth | 14.6% |\n| Revenue growth rate | 62.2% |\n| Future return on equity | 16.90% |\n| Analyst coverage | Low |\n| Last updated | 11 Apr 2025 |\nRecent future growth updates\nRecent updates\nHere's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nSep 21Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?\nMay 29We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate\nFeb 09We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow\nFeb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth\nSep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nMay 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation\nDec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn\nAug 11Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 6/30/2027 | 10 | 1 | 1 | 1 | 1 |\n| 6/30/2026 | 7 | -2 | -2 | -2 | 1 |\n| 6/30/2025 | 2 | -9 | -9 | -9 | N/A |\n| 3/31/2025 | 2 | -9 | -8 | -8 | N/A |\n| 12/31/2024 | 2 | -9 | -8 | -8 | N/A |\n| 9/30/2024 | 2 | -9 | -9 | -9 | N/A |\n| 6/30/2024 | 2 | -10 | -10 | -10 | N/A |\n| 3/31/2024 | 2 | -12 | -11 | -11 | N/A |\n| 12/31/2023 | 2 | -14 | -12 | -12 | N/A |\n| 9/30/2023 | 2 | -14 | -13 | -13 | N/A |\n| 6/30/2023 | 2 | -14 | -14 | -14 | N/A |\n| 3/31/2023 | 2 | -12 | -12 | -12 | N/A |\n| 12/31/2022 | 3 | -9 | -10 | -10 | N/A |\n| 9/30/2022 | 5 | -7 | -7 | -7 | N/A |\n| 6/30/2022 | 8 | -5 | -3 | -3 | N/A |\n| 3/31/2022 | 8 | -5 | -2 | -2 | N/A |\n| 12/31/2021 | 8 | -4 | -1 | -1 | N/A |\n| 9/30/2021 | 5 | -6 | -3 | -3 | N/A |\n| 6/30/2021 | 2 | -8 | -5 | -5 | N/A |\n| 3/31/2021 | 2 | -7 | -5 | -5 | N/A |\n| 12/31/2020 | 3 | -6 | -5 | -5 | N/A |\n| 9/30/2020 | 5 | -5 | -4 | -4 | N/A |\n| 6/30/2020 | 7 | -4 | -3 | -3 | N/A |\n| 3/31/2020 | 6 | -6 | -5 | -5 | N/A |\n| 12/31/2019 | 4 | -8 | -7 | -7 | N/A |\n| 9/30/2019 | 3 | -8 | -7 | -7 | N/A |\n| 6/30/2019 | 1 | -8 | -7 | -7 | N/A |\n| 3/31/2019 | 1 | -7 | N/A | -6 | N/A |\n| 12/31/2018 | 1 | -6 | N/A | -5 | N/A |\n| 9/30/2018 | 1 | -5 | N/A | -4 | N/A |\n| 6/30/2018 | 1 | -5 | N/A | -4 | N/A |\n| 3/31/2018 | 1 | -5 | N/A | -4 | N/A |\n| 12/31/2017 | 1 | -5 | N/A | -5 | N/A |\n| 9/30/2017 | 2 | -5 | N/A | -4 | N/A |\n| 6/30/2017 | 2 | -5 | N/A | -4 | N/A |\n| 3/31/2017 | 2 | -4 | N/A | -3 | N/A |\n| 12/31/2016 | 2 | -3 | N/A | -2 | N/A |\n| 9/30/2016 | 1 | -4 | N/A | -3 | N/A |\n| 6/30/2016 | 1 | -5 | N/A | -4 | N/A |\n| 3/31/2016 | 1 | -5 | N/A | -4 | N/A |\n| 12/31/2015 | 1 | -5 | N/A | -4 | N/A |\n| 9/30/2015 | 1 | -4 | N/A | -4 | N/A |\n| 6/30/2015 | 0 | -4 | N/A | -3 | N/A |\n| 3/31/2015 | 0 | -3 | N/A | -2 | N/A |\n| 12/31/2014 | 0 | -3 | N/A | -2 | N/A |\n| 9/30/2014 | 0 | -3 | N/A | -2 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: CYP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.1%).\nEarnings vs Market: CYP is forecast to become profitable over the next 3 years, which is considered above average market growth.\nHigh Growth Earnings: CYP is expected to become profitable in the next 3 years.\nRevenue vs Market: CYP's revenue (62.2% per year) is forecast to grow faster than the Australian market (5.5% per year).\nHigh Growth Revenue: CYP's revenue (62.2% per year) is forecast to grow faster than 20% per year.\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: CYP's Return on Equity is forecast to be low in 3 years time (16.9%).\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/29 21:04 |\n| End of Day Share Price | 2025/08/29 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2025/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nCynata Therapeutics Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Dennis Hulme | APP Securities Pty Ltd. |\n| Chris Kallos | MST Financial Services Pty Limited |\n| Raghuram Selvaraju | Rodman & Renshaw, LLC |"
    }
  ],
  "argos_summary": "Cynata Therapeutics, a pre\u2011revenue Australian biotech, has a cash runway of roughly seven months as of June\u202f2025, burning AU$8.8\u202fmillion against AU$5.0\u202fmillion in reserves. The company\u2019s free cash flow has declined 12% year\u2011over\u2011year, but analysts project a break\u2011even in about 19 months if burn slows further. With no debt and a modest equity base, the firm may need to raise capital\u2014via equity or debt\u2014to sustain growth and avoid liquidity risk. Investors should monitor the company\u2019s cash burn trajectory and potential funding rounds as catalysts for its valuation and survival prospects.",
  "argos_id": "LWD2CNP8N"
}